Barclays Has Lowered Expectations for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price target reduced by analysts at Barclays from $23.00 to $20.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price objective points to a potential upside of 8.62% from the company’s previous close.

AMPH has been the topic of several other reports. Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Piper Sandler restated a “neutral” rating and set a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Weiss Ratings lowered Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Seven equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Reduce” and a consensus target price of $24.00.

Amphastar Pharmaceuticals Trading Down 0.2%

Shares of AMPH stock opened at $18.41 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The company has a market cap of $811.83 million, a price-to-earnings ratio of 11.02, a PEG ratio of 3.62 and a beta of 0.91. The stock has a 50 day simple moving average of $20.08 and a 200-day simple moving average of $23.79. Amphastar Pharmaceuticals has a 1-year low of $16.65 and a 1-year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. On average, equities research analysts expect that Amphastar Pharmaceuticals will post 2.41 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its holdings in shares of Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after purchasing an additional 228,262 shares during the last quarter. TD Asset Management Inc lifted its position in Amphastar Pharmaceuticals by 1.6% during the fourth quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock worth $52,571,000 after buying an additional 31,160 shares in the last quarter. State Street Corp lifted its position in Amphastar Pharmaceuticals by 2.1% during the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock worth $41,021,000 after buying an additional 31,044 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in Amphastar Pharmaceuticals by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after buying an additional 40,536 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in Amphastar Pharmaceuticals by 41.6% in the 4th quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock valued at $33,134,000 after buying an additional 363,216 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.